Roflumilast (Topical)

Brand names: Zoryve
Drug class: Antineoplastic Agents , Antineoplastic Agents

Usage of Roflumilast (Topical)

Plaque Psoriasis

Roflumilast is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Guidelines for the management of psoriasis with topical and alternative agents state that topical agents are most often used for patients with mild to moderate disease; recommendations are not provided for use of roflumilast, which was approved after publication of the guideline.

Relate drugs

How to use Roflumilast (Topical)

General

Pretreatment Screening

  • Prior to initiating roflumilast, evaluate patients for presence of hepatic dysfunction; roflumilast is contraindicated in patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

    • Other General Considerations

  • In patients who are breastfeeding, use roflumilast on the smallest area of skin and for the shortest duration possible to minimize potential exposure to the breastfed infant via breast milk. Advise breastfeeding patients not to apply roflumilast directly to the nipple or areola to avoid direct infant exposure.

    • Administration

    Oral Administration

    For topical use only. Not for ophthalmic, oral, or intravaginal use. Rub in cream completely until no longer visible on skin. Wash hands after application, unless roflumilast is for treatment of the hands.

    Dosage

    Pediatric Patients

    Plaque Psoriasis Topical

    Pediatric patients ≥12 years of age: Apply once daily to affected areas, including intertriginous areas.

    Adults

    Plaque Psoriasis Topical

    Apply once daily to affected areas, including intertriginous areas.

    Special Populations

    Hepatic Impairment

    Contraindicated in moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

    Renal Impairment

    No specific dosage recommendations.

    Geriatric Patients

    No dosage adjustment necessary; however, greater sensitivity of some older individuals cannot be ruled out.

    Warnings

    Contraindications

  • Moderate to severe liver impairment (Child-Pugh B or C).

    • Warnings/Precautions

    Specific Populations

    Pregnancy

    No adequate human data available on roflumilast use in pregnancy. In animal studies, oral roflumilast administered during the period of organogenesis produced no fetal structural abnormalities at doses up to 9 and 8 times the maximum recommended human dose. Do not use roflumilast during labor and delivery; animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.

    Lactation

    No data regarding the presence of roflumilast in human milk, the effects on the breastfed infant, or the effects on milk production.

    Excreted into milk of lactating rats and therefore, likely to be present in human milk. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for roflumilast and any potential adverse effects on the breastfed infant or from the underlying maternal condition.

    To minimize potential exposure to the breastfed infant via breast milk, use on the smallest area of skin and for the shortest duration possible while breastfeeding. To avoid direct infant exposure, advise breastfeeding patients not to apply roflumilast directly to the nipple and areola.

    Pediatric Use

    Safety and effectiveness established in pediatric patients ages 12 years and older for the treatment of plaque psoriasis.

    Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

    Geriatric Use

    In clinical trials, 106 subjects with psoriasis exposed to roflumilast or vehicle were 65 years of age or older. No overall differences in safety or effectiveness observed between older subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

    Hepatic Impairment

    The AUC and Cmax values of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment when roflumilast was orally administered. Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C).

    Renal Impairment

    Topical roflumilast has not been evaluated in patients with renal impairment. No clinically significant differences in the pharmacokinetics of roflumilast or its roflumilast N-oxide metabolite observed in patients with severe renal impairment following oral administration.

    Common Adverse Effects

    Adverse effects reported in ≥1% of patients with plaque psoriasis in clinical studies and with an incidence exceeding that of vehicle include diarrhea, headache, insomnia, application site pain, upper respiratory tract infections, and urinary tract infections.

    What other drugs will affect Roflumilast (Topical)

    Extensive metabolism via Phase 1 CYP enzyme and Phase II conjugation reactions. In vitro, metabolized by CYP1A2 and CYP3A4. N-oxide metabolite only major metabolite observed in human plasma. Therapeutic plasma concentrations of roflumilast and its N-oxide metabolite do not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A9/11; therefore, interactions with these enzymes unlikely. In vitro, no induction of CYP1A2, 2A6, 2C9, 2C19, or 3A4/5, and only weak induction of CYP2B6.

    No formal drug interaction studies conducted with topical roflumilast.

    Drugs Affecting Hepatic Microsomal Enzymes

    Inhibitors of CYP3A4 and CYP1A2: Based on drug interaction studies, the coadministration of roflumilast with systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and can result in increased adverse effects of roflumilast. Weigh the risks of concurrent use of roflumilast against the potential benefits.

    Specific Drugs and Foods

    Drug

    Interaction

    Comments

    Cimetidine

    Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 46% and 85%, respectively; also decreased the Cmax and increased the AUC of roflumilast N-oxide metabolite by 4% and 27%, respectively

    Risks of concurrent use should be weighed against benefits.

    Enoxacin

    Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 20% and 56%, respectively; also decreased the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 14% and 23%, respectively

    Risks of concurrent use should be weighed against benefits.

    Erythromycin

    Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 40% and 70%, respectively; decreased the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 34% and 4%, respectively

    Risks of concurrent use should be weighed against benefits.

    Fluvoxamine

    Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 12% and 156%, respectively; also decreased the roflumilast N-oxide metabolite Cmax by 210% and increased the AUC by 52%

    Risks of concurrent use should be weighed against benefits.

    Ketoconazole

    Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 23% and 99%, respectively, and reduced the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 38% and 3%, respectively

    Risks of concurrent use should be weighed against benefits.

    Oral contraceptives (containing gestodene and ethinyl estradiol)

    Coadministration with oral roflumilast resulted in a 38% increase and 12% decrease in the Cmax of roflumilast and roflumilast N-oxide, respectively Roflumilast and roflumilast N-oxide metabolite AUCs increased by 51% and 14%, respectively

    Risks of concurrent use should be weighed against benefits.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant